Abstract:Abstract Objectives Androgenic alopecia is characterized by a receding hairline and hair loss from the frontal scalp. This genetic condition affects approximately 80% of men and 42% of women. Finasteride is the only oral treatment currently approved by the FDA to prevent and treat androgenic alopecia, and it is currently prescribed to over nine million males in the US. Recent claims suggest that long-term use of finasteride could have detrimental health effects by affecting the lipid profile in people. Finasteride prevents the conversion of testosterone to its active metabolite dihydrotestosterone by inhibiting the type II 5 alpha-reductase, which is predominantly present in the hair follicle and the prostate. As a result, finasteride alters the systemic levels of testosterone and its derivative estradiol. Hormone homeostasis affects plasma lipid levels, therefore we hypothesize that supplementation with finasteride will affect systemic lipid profile in atheroprone low-density lipoprotein receptor (Ldlr−/−) mice fed a Western diet (high cholesterol, high fat). Methods We fed six-week-old male Ldlr−/-mice (10/group) fed a Western diet (control) or a Western diet supplemented with 10 mg Finasteride/kg diet for 12 weeks. We monitored body weight progression and food intake during the entire experiment. A week before harvesting the tissues, mice were fasted overnight to perform a glucose tolerance test. At the moment of sacrifice, final body weight and several tissues were collected such as the inguinal, retroperitoneal, and gonadal adipose tissues, skeletal muscle (gastrocnemius), and liver. Plasma was harvested to determine total cholesterol and triglyceride levels. Results Our data show that 12-week supplementation with a low dose of finasteride does not have a significant impact on food intake, body weight, or adiposity index. We did not observe any significant change in plasma lipids or glucose tolerance. Conclusions A low dose of finasteride supplemented for 12 weeks does not alter the lipid profile in the atheroprone Ldlr−/-mouse model, nor alters adiposity index. These data indicate that finasteride does not have detrimental effects on these metabolic parameters. Funding Sources U.S. Department of Agriculture (Multi-State grant project W4002).

Dietary Supplementation with a Low Dose of Finasteride Does Not Alter the Lipid Profile of Ldlr-Deficient Mice

Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men

Finasteride delays atherosclerosis progression in mice and is associated with a reduction in plasma cholesterol in men

Effects of Stigmasterol and Β-Sitosterol on Nonalcoholic Fatty Liver Disease in a Mouse Model: A Lipidomic Analysis.

Long-term treatment with finasteride induces apoptosis and pathological changes in female mice

Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia

The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids

A Double Blind Randomized Placebo Controlled Clinical Trial of Finasteride in the Treatment of Androgenetic Alopecia

Finasteride for hair loss: a review

Persistent Gynecomastia due to Short-term Low-dose Finasteride for Androgenetic Alopecia

Ginsenoside F2 reduces hair loss by controlling apoptosis through the sterol regulatory element-binding protein cleavage activating protein and transforming growth factor-β pathways in a dihydrotestosterone-induced mouse model.

Effects of hig hfat diet on reproductive func tion and the expression of Ox-LDL within testis in male mice

(379) The Effect of 5-α Reductase Inhibitor on Male Reproductive Function

Finasteride-Induced Inhibition of 5α-Reductase Type 2 Could Lead to Kidney Damage—Animal, Experimental Study

Abstract A105: Androgen Regulation of 5Α-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention

Investigation of Oral Finasteride Enhanced Occipital Hair Diameter Index in Different Types of Male Androgenetic Alopecia.

Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial

Serum uric acid level in male patients with androgenetic alopecia: A prospective study in China

Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss

Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients

Novel natural lipids based NLC containing finasteride improved androgenetic alopecia treatment in rats